ARESTOCAINE HYDROCHLORIDE

Post-LOE

mepivacaine hydrochloride

Sanofi

ANDAINJECTIONINJECTABLE

Approved

Dec 1975

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

ARESTOCAINE HYDROCHLORIDE (mepivacaine hydrochloride) by Sanofi is clinical pharmacology: scandonest stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia. First approved in 1975.

Drug data last refreshed 3d ago

Mechanism of Action

CLINICAL PHARMACOLOGY: SCANDONEST stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia. SCANDONEST is rapidly metabolized, with only a small percentage of the anesthetic (5 to 10 percent) being excreted unchanged in the…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Worked on ARESTOCAINE HYDROCHLORIDE at Sanofi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.